A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-10

Study Completion Date

2023-03-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out whether romiplostim can help prevent low platelet counts caused by N8 or EFT chemotherapy, reduce the number of platelet transfusions required during chemotherapy, and prevent treatment delays due to low platelet counts.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients

NCT07043894

Solid Tumors Hematological Tumor Children +2 more

NOT_YET_RECRUITING PHASE2

Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

NCT00006462

Leukemia

COMPLETED PHASE2

Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy

NCT00187109

Germ Cell Tumors Hepatic Cancer Neuroblastoma +2 more

COMPLETED PHASE1/PHASE2

Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

NCT00003735

Leukemia

COMPLETED PHASE2

Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

NCT00024284

Unspecified Childhood Solid Tumor, Protocol Specific

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor Solid Tumor, Childhood Solid Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pediatric Participants

Male and female patients aged 1-21 years with a primary solid tumor undergoing treatment with the pre-defined chemotherapy regimens of EFT, MAP or D9803.

Group Type EXPERIMENTAL

Romiplostim

Intervention Type DRUG

Participants will receive weekly doses of romiplostim, beginning with cycle 4. The initial romiplostim dose will be 10 mcg/kg, and subsequent doses w ill vary based on chemotherapy regimen for a target of platelet count \> 75,000- 200,000/mcL. Participants will continue romiplostim until completion of MAP or D9803, as defined above. Maximum romiplostim dose is 10 mcg/kg. Participants will be followed until 6 months after the last dose of romiplostim.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Romiplostim

Participants will receive weekly doses of romiplostim, beginning with cycle 4. The initial romiplostim dose will be 10 mcg/kg, and subsequent doses w ill vary based on chemotherapy regimen for a target of platelet count \> 75,000- 200,000/mcL. Participants will continue romiplostim until completion of MAP or D9803, as defined above. Maximum romiplostim dose is 10 mcg/kg. Participants will be followed until 6 months after the last dose of romiplostim.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented diagnosis of a primary solid tumor. Patients must have histological verification of malignancy at MSKCC.
* Male and female patients aged 1-21 years with a primary solid tumor undergoing treatment with the pre-defined chemotherapy regimens of EFT, MAP, D9803. Prior to enrollment patient could have been undergoing induction therapy with a similarly myelosuppressive regimen as long as they will be continuing with EFT, MAP, D9803 at the time of study enrollment.
* Patients undergoing treatment with MAP chemotherapy w ho have had ≥ 1 platelet transfusion during induction stage of treatment.
* Total Bilirubin (sum of conjugated + unconjugated) ≤ 3 times institutional upper limit of normal (ULN) for age and ALT/AST ≤ 3 times institutional ULN for age.
* Normal cardiac function:

* Shortening fraction greater than or equal to 28% by echocardiogram OR Left ventricular ejection fraction (LVEF) greater than or equal to 50% on technetium- 99m pertechnetate radionuclide cineangiography (MUGA) or echocardiogram.
* Screening ECG with corrected QT (QTc) interval of \< 470 msec.
* Timing of cardiac assessment: We will utilize the most recent EKG/ECHO when assessing cardiac function. See section 9.0 for additional details.
* Adequate renal function, defined as an estimated Creatinine Clearance or GFR \>40ml/min or an normal creatine for age (see below)

Serum Creatinine by age:

Age (years) \<6: Maximum Serum Creatinine (mg/dL), Male 0.8, Female 0.8 Age (years) 6 to \<10: Maximum Serum Creatinine (mg/dL), Male 1, Female 1 Age (years) 10 to \<13: Maximum Serum Creatinine (mg/dL), Male 1.2, Female 1.2 Age (years) 13 to \<16: Maximum Serum Creatinine (mg/dL), Male 1.5, Female 1.4 Age (years) \>16: Maximum Serum Creatinine (mg/dL), Male 1.7, Female 1.4

These threshold creatine values were derived from the Scwartz formula estimating GFR, utilizing child length and statured published by the CDC.

Exclusion Criteria

* Patients with history of hematologic malignancies or allogenic/autogenic stem cell transplant.
* Patients with a currently known predisposition to a myeloid stem cell disorder, myeloid leukemia, and/or bone marrow failure syndrome including, but not limited to:

* Aplastic anemia
* Ataxia telangiectasia
* Bloom syndrome
* Congenital amegakaryocytic thrombocytopenia
* Cyclic neutropenia
* Diamond Blackfan anemia
* Dyskeratosis congenita
* Familial AML/MDS syndromes (including ANKRD26, CEBPA, DDX41, ETV6, GATA2, RUNX1, SRP72)
* Fanconi anemia
* Kostmann disease
* Li-Fraumeni syndrome
* Neurofibromatosis
* Nijmegen breakage syndrome
* Noonan syndrome
* Paroxysmal nocturnal hemoglobinuria
* Pearson syndrome
* Poland syndrome
* Rothmund-Thomson syndrome
* Severe congenital neutropenia
* Thrombocytopenia absent radii syndrome
* Trisomy 8
* Trisomy 21
* WHIM syndrome
* Wiskott Aldrich syndrome
* Xeroderma pigmentosa
* Secondary malignancy in the past 5 years.
* Patients who have previously undergone up-front chemotherapy and have relapsed or progressed through therapy.
* Patients who have received 4 or more cycles of induction chemotherapy for their current malignancy prior to time of enrollment.
* Previous use of romiplostim, eltrombopag, recombinant human TPO, or any other TPO receptor agonist, or any investigational platelet producing agent.
* Patients receiving other investigational agents are not eligible for study entry.

History of uncontrolled arrhythmias, clinically significant electrocardiogram (ECG) abnormalities, active heart failure or pericardial disease.

* Patients with current or prior venous thrombotic event or arterial thrombotic event at time of enrollment will be ineligible for this study.
* Pregnant women/lactating mothers.
* Patients unwilling to use effective contraception method, which includes abstinence.
* Patients with an inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.

Minimum Eligible Age

1 Year

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No